A principled approach to setting optimal diagnostic thresholds: where ROC and indifference curves meet.

R. Irwin,Timothy C. Irwin

DOI: https://doi.org/10.1016/j.ejim.2010.12.012

IF: 7.749

2011-06-01

European Journal of Internal Medicine

Abstract:

What problem does this paper attempt to address?

Does stage of change predict improved intimate partner violence outcomes following an emergency department intervention?

Justin D. Schrager,L. Smith,S. Heron,D. Houry

DOI: https://doi.org/10.1111/acem.12081

2013-02-01

Academic Emergency Medicine

Abstract:OBJECTIVES The objective was to assess the effect of an emergency department (ED)-based computer screening and referral intervention on the safety-seeking behaviors of female intimate partner violence (IPV) victims at differing stages of change. The study also aimed to determine which personal and behavioral characteristics were associated with a positive change in safety-seeking behavior. The hypothesis was that women who were in contemplation or action stages of change would be more likely to endorse safety behaviors during follow-up. METHODS This was a prospective cohort study of female IPV victims at three urban EDs, using a computer kiosk to deliver targeted education about IPV to provide referrals to local resources. All noncritically ill adult English-speaking women triaged to the ED waiting room during study hours were eligible to participate. Women were screened for IPV using the validated Universal Violence Prevention Screening Protocol (UVPSP), and all IPV-positive women further responded to validated questionnaires for alcohol and drug abuse, depression, and IPV severity. The women were assigned a baseline stage of change using the University of Rhode Island Change Assessment (URICA) scale for readiness to change their IPV behaviors. Study participants were contacted at 1 week and 3 months to assess a variety of predetermined safety behaviors to prevent further IPV during that period. Descriptive analyses were performed to determine if stage of change at enrollment and a variety of specific sociodemographic characteristics were associated with taking protective action during follow-up. RESULTS A total of 1,474 women were screened for IPV; 154 (10.4%) disclosed IPV and completed the full survey. Approximately half (47.4%) of the IPV victims were in the precontemplation stage of change, and 50.0% were in the contemplation stage. A total of 110 women returned at 1 week of follow-up (71.4%), and 63 (40.9%) women returned for the 3-month follow-up. Fifty-five percent of those who returned at 1 week and 73% of those who returned at 3 months took protective action against further IPV. Stage of change at enrollment was not significantly associated with taking protective action during follow-up. There was no association between demographic characteristics and taking protective action at 1 week or 3 months. CONCLUSIONS Emergency department-based kiosk screening and health information delivery is a feasible method of health information dissemination for women experiencing IPV and was associated with a high proportion of study participants taking protective action. Stage of change was not associated with actual IPV protective measures.
Acute systemic melioidosis: an autopsy study of six cases.

K. Atisook,R. Panyathanya

1988-12-01

Southeast asian journal of tropical medicine and public health

Abstract:Autopsy findings of six cases of the acute systemic melioidosis from Siriraj Hospital, Bangkok, Thailand during the years 1977 to 1986 are presented. Five out of six cases had some underlying conditions. Multiple abscesses and multiple organs involvement were the rule. The organs most commonly involved were lung and liver. Three patients had pericardial and one had adrenal gland involvement. Other significant pathological findings were fibrin thrombi (5/6 cases), haemorrhage (6/6 cases), tissue necrosis (4/6 cases) and granular casts in renal tubules (1/6 case). Abscess alone cannot explain the death of patients. Toxaemia, both exotoxins and endotoxin, is the most likely explanation from the death of patients.
Inhibition of MAPK stimulates the Ca2+-dependent big-conductance K channels in cortical collecting duct

Dimin Li,Zhijian Wang,Peng Sun,Yan Jin,Daohong Lin,S. Hebert,G. Giebisch,Wen‐Hui Wang

DOI: https://doi.org/10.1073/pnas.0609555104

2006-12-19

Abstract:The kidney plays a key role in maintaining potassium (K) homeostasis. K excretion is determined by the balance between K secretion and absorption in distal tubule segments such as the connecting tubule and cortical collecting duct. K secretion takes place by K entering principal cells (PC) from blood side through Na+, K+-ATPase and being secreted into the lumen via both ROMK-like small-conductance K (SK) channels and Ca2+-activated big-conductance K (BK) channels. K reabsorption occurs by stimulation of apical K/H-ATPase and inhibition of K recycling across the apical membrane in intercalated cells (IC). The role of ROMK channels in K secretion is well documented. However, the importance of BK channels in mediating K secretion is incompletely understood. It has been shown that their activity increases with high tubule flow rate and augmented K intake. However, BK channels have a low open probability and are mainly located in IC, which lack appropriate transporters for effective K secretion. Here we demonstrate that inhibition of ERK and P38 MAPKs stimulates BK channels in both PC and IC in the cortical collecting duct and that changes in K intake modulate their activity. Under control conditions, BK channel activity in PC was low but increased significantly by inhibition of both ERK and P38. Blocking MAPKs also increased channel open probability of BK in IC and thereby it may affect K backflux and net K absorption Thus, modulation of ERK and P38 MAPK activity is involved in controlling net K secretion in the distal nephron.
Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors

Takuya Kobayakawa,Kohei Tsuji,Kiju Konno,Ai Himeno,Ami Masuda,Tingting Yang,Kohei Takahashi,Yusuke Ishida,Nami Ohashi,Takeo Kuwata,Kaho Matsumoto,Kazuhisa Yoshimura,Hiromi Sakawaki,Tomoyuki Miura,Shigeyoshi Harada,Shuzo Matsushita,Hirokazu Tamamura

DOI: https://doi.org/10.1021/acs.jmedchem.0c01153

IF: 8.039

2021-01-26

Journal of Medicinal Chemistry

Abstract:CD4 mimics are small molecules that inhibit the interaction of gp120 with CD4. We have developed several CD4 mimics. Herein, hybrid molecules consisting of CD4 mimics with a long alkyl chain or a PEG unit attached through a self-cleavable linker were synthesized. In anti-HIV activity, modification with a PEG unit appeared to be more suitable than modification with a long alkyl chain. Thus, hybrid molecules of CD4 mimics, with PEG units attached through an uncleavable linker, were developed and showed high anti-HIV activity and low cytotoxicity. In investigation of pharmacokinetics in a rhesus macaque, a hybrid compound had a more effective PK profile than that of the parent compound, and intramuscular injection was a more useful administration route to maintain the high blood concentration of the CD4 mimic than intravenous injection. The presented hybrid molecules of CD4 mimics with a PEG unit would be practically useful when combined with a neutralizing antibody.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01153?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01153</a>.Experimental procedures of compound synthesis including characterization data, a calibration curve of YIR-821·2TFA used to calculate PK in a rhesus macaque, degradation experiments of the hybrid molecule 45 in the PBS solution (pH 7.4) at 37 °C, a calibration curve of the hybrid molecule 58·2TFA used to calculate PK in a rhesus macaque by iv injection, a calibration curve of 58·2TFA used to calculate PK in a rhesus macaque by im injection, the structures of YIR-821 and compound 58 docked in gp120, HPLC analysis of evaluation of the biological stability of compound 58·2TFA treated with human liver microsomes, FACS analysis of EGFP and HIV-1 JR-FL envelope (Env) expressing HEK293T cells treated with anti-CD4i antibodies, and inhibition of gp120-CD4 binding by compound 58 and YIR-821 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01153/suppl_file/jm0c01153_si_001.pdf">PDF</a>)Molecular formula strings of 2–22, 24, 30, 32, 35, 36, 38–46, 49, 50, 54, 58, and 62 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01153/suppl_file/jm0c01153_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

chemistry, medicinal
A minimally cytotoxic CD4 mimic as an HIV entry inhibitor

Takaaki Mizuguchi,Shigeyoshi Harada,Tomoyuki Miura,Nami Ohashi,Tetsuo Narumi,Hiromi Mori,Yu Irahara,Yuko Yamada,Wataru Nomura,Shuzo Matsushita,Kazuhisa Yoshimura,Hirokazu Tamamura

DOI: https://doi.org/10.1016/j.bmcl.2015.11.103

2016-01-15

Abstract:Several CD4 mimics have been reported as HIV-1 entry inhibitors which can block the interaction between the viral envelope glycoprotein gp120 and the cell surface protein CD4. We previously found a lead compound 2 (YYA-021) with high anti-HIV activity and low cytotoxicity. Pharmacokinetic analysis however showed compound 2 to have wide tissue distribution and relatively high distribution volumes in rats and rhesus macaques. In the present study we searched for more hydrophilic CD4 mimics with a view to reducing tissue distribution. A new compound (5) with a 1,3-benzodioxolyl moiety was found to have relatively high anti-HIV activity and no significant cytotoxicity. Compound 5 is more hydrophilic than compound 2 and the pharmacokinetics of the intravenous administration of compound 5 in a rhesus macaque showed that compound 5 has lower tissue distribution than compound 2, suggesting that compound 5 possesses a better profile.
Healing of the bone incision following Le Fort I osteotomy.

J. E. Compton,J. Jacobs,A. R. Dunsworth

DOI: https://doi.org/10.1016/0278-2391(84)90209-X

IF: 1.9

1984-10-01

Journal of Oral and Maxillofacial Surgery

Abstract:
In Silico Identification of Novel Aromatic Compounds As Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4

Alexander M. Andrianov,Grigory I. Nikolaev,Yuri V. Kornoushenko,Wei Xu,Shibo Jiang,Alexander V. Tuzikov

DOI: https://doi.org/10.3390/v11080746

2019-01-01

Abstract:Despite recent progress in the development of novel potent HIV-1 entry/fusion inhibitors, there are currently no licensed antiviral drugs based on inhibiting the critical interactions of the HIV-1 envelope gp120 protein with cellular receptor CD4. In this connection, studies on the design of new small-molecule compounds able to block the gp120-CD4 binding are still of great value. In this work, in silico design of drug-like compounds containing the moieties that make the ligand active towards gp120 was performed within the concept of click chemistry. Complexes of the designed molecules bound to gp120 were then generated by molecular docking and optimized using semiempirical quantum chemical method PM7. Finally, the binding affinity analysis of these ligand/gp120 complexes was performed by molecular dynamic simulations and binding free energy calculations. As a result, five top-ranking compounds that mimic the key interactions of CD4 with gp120 and show the high binding affinity were identified as the most promising CD4-mimemic candidates. Taken together, the data obtained suggest that these compounds may serve as promising scaffolds for the development of novel, highly potent and broad anti-HIV-1 therapeutics.
Hybrids of small CD4 mimics and gp41-related peptides as dual-target HIV entry inhibitors

Rongyi Wang,Kohei Tsuji,Takuya Kobayakawa,Yishan Liu,Kazuhisa Yoshimura,Shuzo Matsushita,Shigeyoshi Harada,Hirokazu Tamamura

DOI: https://doi.org/10.1016/j.bmc.2022.117083

2022-12-15

Abstract:Hybrid molecules containing small CD4 mimics and gp41-C-terminal heptad repeat (CHR)-related peptides have been developed. A YIR-821 derivative was adopted as a CD4 mimic, which inhibits the interaction of gp120 with CD4. SC-peptides, SC34 and SC22EK, were also used as CHR-related peptides, which inhibit the interaction between the N-terminal heptad repeat (NHR) and CHR and thereby membrane fusion. Therefore, these hybrid molecules have dual-targets of gp120 and gp41. In the synthesis of the hybrid molecules of CD4 mimic-SC-peptides with different lengths of linkers, two conjugating methods, Cu-catalyzed azide-alkyne cycloaddition and direct cysteine alkylation, were performed. The latter reaction caused simpler operation procedures and higher synthetic yields than the former. The synthesized hybrid molecules of CD4 mimic-SC22EK have significantly higher anti-HIV activity than each sole agent. The present data should be useful in the future design of anti-HIV agents as dual-target entry inhibitors.
In Silico Identification of High-Affinity Ligands of the Hiv-1 Gp120 Protein, Potential Peptidomimetics of Neutralizing Antibody N6

A.M. Andrianov,G.I. Nikolaev,Y.V. Kornoushenko,J. Huang,S. Jiang,A.V. Tuzikov

DOI: https://doi.org/10.17537/2019.14.430

2019-01-01

Abstract:Six potential peptidomimetics of the cross-reactive neutralizing anti-HIV-1 antibody N6 that are able to mimic the pharmacophoric features of this immunoglobulin by specific and effective interactions with the CD4-binding site of the viral gp120 protein were identified by virtual screening and molecular modeling. The key role in the interaction of these compounds with gp120 is shown to play multiple van der Waals contacts with conserved residues of the gp120 Phe-43 cavity critical for the HIV binding to cellular receptor CD4, as well as hydrogen bond with Asp-368gp120 that increase the chemical affinity without activating unwanted allosteric effect. According to the data of molecular dynamics, the complexes of the identified ligands with gp120 are energetically stable and show the lower values of binding free energy compared with the HIV-1 inhibitors NBD-11021 and DMJ-II-121 used in the calculations as a positive control. Based on the data obtained, it was concluded that the identified compounds may be considered as promising candidates for detailed experimental studies to their further use in the design of novel antiviral drugs presenting HIV-1 inhibitors that block the early stages of the development of HIV infection.
N-Phenyl-N'-(2,2,6,6-Tetramethyl-Piperidin-4-Yl)-Oxalamides As A New Class Of Hiv-1 Entry Inhibitors That Prevent Gp120 Binding To Cd4

Q Zhao,Ly Ma,Sb Jiang,H Lu,Sw Liu,Yx He,N Strick,N Neamati,Ak Debnath

DOI: https://doi.org/10.1016/j.virol.2005.06.008

IF: 3.513

2005-01-01

Virology

Abstract:We have identified two N-phenyt-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide analogs as a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitors that block the gp120-CD4 interaction, using database screening techniques. The lead compounds, NBD-556 and NBD-557, are small molecule organic compounds with drug-like properties. These compounds showed potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels. A systematic study showed that these compounds target viral entry by inhibiting the binding of HIV-1 envelope glycoprotein gp120 to the cellular receptor CD4 but did not inhibit reverse transcriptase, integrase, or protease, indicating that they do not target the later stages of the HIV-1 life cycle to inhibit HIV-1 infection. These compounds were equally potent inhibitors of both X4 and R5 viruses tested in CXCR4 and CCR5 expressing cell tines, respectively, indicating that their anti-HIV-1 activity is not dependent on the coreceptor tropism of the virus. A surface plasmon resonance study, which measures binding affinity, clearly demonstrated that these compounds bind to unliganded HIV-1 gp120 but not to the cellular receptor CD4. NBD-556 and NBD-557 were active against HIV-1 laboratory-adapted strains including ail AZT-resistant strain and HIV-1 primary isolates, indicating that these compounds can potentially be further modified to become potent HIV-1 entry inhibitors. (c) 2005 Elsevier Inc. All rights reserved.
Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4

Qian Zhao,Liying Ma,Shibo Jiang,Hong Lu,Shuwen Liu,Yuxian He,Nathan Strick,Nouri Neamati,Asim Kumar Debnath

DOI: https://doi.org/10.1016/j.virol.2005.06.008

IF: 3.513

2005-01-01

Virology

Abstract:We have identified two N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide analogs as a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitors that block the gp120–CD4 interaction, using database screening techniques. The lead compounds, NBD-556 and NBD-557, are small molecule organic compounds with drug-like properties. These compounds showed potent cell fusion and virus–cell fusion inhibitory activity at low micromolar levels. A systematic study showed that these compounds target viral entry by inhibiting the binding of HIV-1 envelope glycoprotein gp120 to the cellular receptor CD4 but did not inhibit reverse transcriptase, integrase, or protease, indicating that they do not target the later stages of the HIV-1 life cycle to inhibit HIV-1 infection. These compounds were equally potent inhibitors of both X4 and R5 viruses tested in CXCR4 and CCR5 expressing cell lines, respectively, indicating that their anti-HIV-1 activity is not dependent on the coreceptor tropism of the virus. A surface plasmon resonance study, which measures binding affinity, clearly demonstrated that these compounds bind to unliganded HIV-1 gp120 but not to the cellular receptor CD4. NBD-556 and NBD-557 were active against HIV-1 laboratory-adapted strains including an AZT-resistant strain and HIV-1 primary isolates, indicating that these compounds can potentially be further modified to become potent HIV-1 entry inhibitors.
Effect of modification of N-acetylneuraminic acid on the binding of glycoproteins to influenza virus and on susceptibility to cleavage by neuraminidase.

M. Suttajit,R. Winzler

DOI: https://doi.org/10.1016/s0021-9258(18)62237-9

IF: 5.485

1971-05-25

Journal of Biological Chemistry

Abstract:
A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region

Chao Wang,Xinling Wang,Huan Wang,Jing Pu,Qing Li,Jiahui Li,Yang Liu,Lu Lu,Shibo Jiang

DOI: https://doi.org/10.1021/acs.jmedchem.1c00781

IF: 8.039

2021-07-15

Journal of Medicinal Chemistry

Abstract:Previous studies have reported the stepwise nature of human immunodeficiency virus type 1 (HIV-1) entry and the pivotal role of coreceptor CCR5 and the gp41 N-terminal heptad repeat (NHR) region in this event. With this in mind, we herein report a dual-targeted drug compound featuring bifunctional entry inhibitors, consisting of a piperidine-4-carboxamide-based CCR5 antagonist, TAK-220, and a gp41 NHR-targeting fusion-inhibitory peptide, C34. The resultant chimeras were constructed by linking both pharmacophores with a polyethylene glycol spacer. One chimera, CP12TAK, exhibited exceptionally potent antiviral activity, about 40- and 306-fold over that of its parent inhibitors, C34 and TAK-220, respectively. In addition to R5-tropic viruses, CP12TAK also strongly inhibited infection of X4-tropic HIV-1 strains. These data are promising for the further development of CP12TAK as a new anti-HIV-1 drug. Results show that this strategy could be extended to the design of therapies against infection of other enveloped viruses.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00781?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00781</a>.HPLC method used for the purification of peptide compounds; HPLC method used for the analysis of peptide compounds; potential cytotoxicity of CP12TAK on CEMx174 5.25M7 and MT-2 cells; MALDI-TOF-MS and Analytical HPLC of designed peptides; 1H and 13C NMR spectra of small-molecule compounds; and ESI-TOF-MS spectra of small-molecule compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00781/suppl_file/jm1c00781_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00781/suppl_file/jm1c00781_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

chemistry, medicinal
Structural Mimicry of CD4 by a Cross-reactive HIV-1 Neutralizing Antibody with CDR-H2 and H3 Containing Unique Motifs

P Prabakaran,JH Gan,YQ Wu,MY Zhang,DS Dimitrov,XH Ji

DOI: https://doi.org/10.1016/j.jmb.2005.12.062

2006-01-01

Abstract:Human immunodeficiency virus (HIV) entry into cells is initiated by the binding of its envelope glycoprotein (Env) gp120 to receptor CD4. Antibodies that bind to epitopes overlapping the CD4-binding site (CD4bs) on gp120 can prevent HIV entry by competing with cell-associated CD4; their ability to outcompete CD4 is a major determinant of their neutralizing potency and is proportional to their avidity. The breadth of neutralization and the likelihood of the emergence of antibody-resistant virus are critically dependent on the structure of their epitopes. Because CD4bs is highly conserved, it is reasonable to hypothesize that antibodies closely mimicking CD4 could exhibit relatively broad cross-reactivity and a high probability of preventing the emergence of resistant viruses. Previously, in a search for antibodies that mimic CD4 or the co-receptor, we identified and characterized a broadly cross-reactive HIV-neutralizing CD4bs human monoclonal antibody (hmAb), m18. Here, we describe the crystal structure of Fab m18 at 2.03 A resolution, which reveals unique conformations of heavy chain complementarity-determining regions (CDRs) 2 and 3 (H2 and H3). H2 is highly bulged and lacks cross-linking interstrand hydrogen bonds observed in all four canonical structures. H3 is 17.5 A long and rigid, forming an extended beta-sheet decorated with an alpha-turn motif bearing a phenylalanine-isoleucine fork at the apex. It shows striking similarity to the Ig CDR2-like C'C'' region of the CD4 first domain D1 that dominates the binding of CD4 to gp120. Docking simulations suggest significant similarity between the m18 epitope and the CD4bs on gp120. Fab m18 does not enhance binding of CD4-induced (CD4i) antibodies, nor does it induce CD4-independent fusion mediated by the HIV Env. Thus, vaccine immunogens based on the m18 epitope structure are unlikely to elicit antibodies that could enhance infection. The structure can also serve as a basis for the design of novel, highly efficient inhibitors of HIV entry.
Small-Molecule HIV Entry Inhibitors Targeting Gp120 and Gp41

Fei Yu,Shibo Jiang

DOI: https://doi.org/10.1007/978-981-16-8702-0_3

2022-01-01

Advances in experimental medicine and biology

Abstract:Interrupting early events in the virus life cycle, such as those prior to the formation of provirus, could effectively prevent HIV-1 infection. HIV-1 entry into host cells is mediated by the envelope glycoprotein (Env) trimer, which is composed of three gp120 exterior glycoproteins and three gp41 transmembrane glycoproteins. Hence, the development of novel inhibitors targeting these two glycoproteins could hold the key to early inhibition of HIV-1 infection. Small-molecule entry inhibitors targeting early events in the virus life cycle comprise a well-established class of useful drugs. Many libraries of small-molecule inhibitors have been established to screen potential drug candidates for a variety of targets based on computer docking, FRET, or peptide-linked assay. This chapter reviews the mechanisms of some small-molecule inhibitors targeting HIV-1 gp120 and gp41 and corresponding high-efficiency screening strategies for potential small-molecule inhibitors.
Application of deep learning and molecular modeling to identify small drug-like compounds as potential HIV-1 entry inhibitors

Alexander M. Andrianov,Grigory I. Nikolaev,Nikita A. Shuldov,Ivan P. Bosko,Arseny I. Anischenko,Alexander V. Tuzikov

DOI: https://doi.org/10.1080/07391102.2021.1905559

2021-04-15

Journal of Biomolecular Structure and Dynamics

Abstract:A generative adversarial autoencoder for the rational design of potential HIV-1 entry inhibitors able to block CD4-binding site of the viral envelope protein gp120 was developed. To do this, the following studies were carried out: (i) an autoencoder architecture was constructed; (ii) a virtual compound library of potential anti-HIV-1 agents for training the neural network was formed by the concept of click chemistry allowing one to generate a large number of drug candidates by their assembly from small modular units; (iii) molecular docking of all compounds from this library with gp120 was made and calculations of the values of binding free energy were performed; (iv) molecular fingerprints of chemical compounds from the training dataset were generated; (v) training of the developed autoencoder was implemented followed by the validation of this neural network using more than 21 million molecules from the ZINC15 database. As a result, three small drug-like compounds that exhibited the high-affinity binding to gp120 were identified. According to the data from molecular docking, machine learning, quantum chemical calculations, and molecular dynamics simulations, these compounds show the low values of binding free energy in the complexes with gp120 similar to those calculated using the same computational protocols for the HIV-1 entry inhibitors NBD-11021 and NBD-14010, highly potent and broad anti-HIV-1 agents presenting a new generation of the viral CD4 antagonists. The identified CD4-mimetic candidates are suggested to present good scaffolds for the design of novel antiviral drugs inhibiting the early stages of HIV-1 infection.Communicated by Ramaswamy H. Sarma
Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule–Peptide Conjugates As New HIV-1 Fusion Inhibitors

Chao Wang,Weiguo Shi,Lifeng Cai,Lu,Qian Wang,Tianhong Zhang,Jinglai Li,Zhenqing Zhang,Kun Wang,Liang Xu,Xifeng Jiang,Shibo Jiang,Keliang Liu

DOI: https://doi.org/10.1021/jm3018964

IF: 8.039

2013-01-01

Journal of Medicinal Chemistry

Abstract:The small molecule fusion inhibitors N-(4-carboxy-3-hydroxyphenyl)-2,5-dimethylpyrrole (NB-2) and N-(3-carboxy-4-hydroxyphenyl)-2,S-dimethylpyrrole (A(12)) target a hydrophobic pocket of HIV-1 gp41 and have moderate anti-HIV-1 activity. In this paper, we report the design, synthesis, and structure-activity relationship of a group of hybrid molecules in which the pocket-binding domain segment of the C34 peptide was replaced with NB-2 and A(12) derivatives. In addition, the synergistic effect between the small molecule and peptide moieties was analyzed, and lead compounds with a novel scaffold were discovered. We found that either the nonpeptide or peptide part alone showed weak activity against HIV-1-mediated cell-cell fusion, but the conjugates properly generated a strong synergistic effect. Among them, conjugates Aoc-beta Ala-P26 and Noc-beta Ala-P26 exhibited a low nanomolar IC50 in the cell-cell fusion assay and effectively inhibited T20-sensitive and -resistant HIV-1 strains. Furthermore, the new molecules exhibited better stability against proteinase K digestion than T20 and C34.
IDENTIFICATION OF FUNCTIONAL MIMETICS OF ANTI-HIV ANTIBODY N6 BY METHODS OF VIRTUAL SCREENING AND MOLECULAR MODELING

Alexander M. Andrianov,Grigory I. Nikolaev,Yuri V. Kornoushenko,Anna D. Karpenko,Jinghe Huang,Shibo Jiang,Alexander V. Tuzikov

DOI: https://doi.org/10.29235/1561-8323-2019-63-5-561-571

2019-01-01

Abstract:Three chemical compounds presenting functional mimetics of neutralizing anti-HIV-1 antibody N6 were identified by an integrated approach including virtual screening, high-throughput docking and molecular dynamics. Using molecular docking, the identified compounds are predicted to be able to block three key regions of the HIV-1 gp120 protein by formation of a wide network of intermolecular contacts with the glycoprotein residues critical for the virus binding to primary receptor CD4. It is shown that the complexes of these compounds with gp120 exhibit low values of dissociation constant and Gibbs free energy, which validates a high efficacy of intermolecular interactions stabilizing these supramolecular structures. Based on the data obtained, the identified compounds are assumed to form promising basic structures for the development of novel, potent and broad anti-HIV-1 drugs mimicking structural and functional properties of the cross-reactive neutralizing antibody N6.
N-Substituted Pyrrole Derivative 12m Inhibits HIV-1 Entry by Targeting Gp41 of HIV-1 Envelope Glycoprotein

Jiayin Qiu,Taizhen Liang,Junyan Wu,Fei Yu,Xiaoyang He,Yuanxin Tian,Lan Xie,Shibo Jiang,Shuwen Liu,Lin Li

DOI: https://doi.org/10.3389/fphar.2019.00859

IF: 5.6

2019-01-01

Frontiers in Pharmacology

Abstract:The combination of three or more antiviral agents that act on different targets is known as highly active antiretroviral therapy (HAART), which is widely used to control HIV infection. However, because drug resistance and adverse effects occur after long-term administration, an increasing number of HIV/AIDS patients do not tolerate HAART. It is necessary to continue developing novel anti-HIV drugs, particularly HIV entry/fusion inhibitors. Our group previously identified a small-molecule compound, NB-64, with weak anti-HIV activity. Here, we found that N-substituted pyrrole derivative 12m (NSPD-12m), which was derived from NB-64, had strong anti-HIV-1 activity, and NSPD-12m-treated cells showed good viability. The mechanism of action of NSPD-12m might be targeting the gp41 transmembrane subunit of the HIV envelope glycoprotein, thus inhibiting HIV entry. Site-directed mutagenesis confirmed that a positively charged lysine residue (K574) located in the gp41 pocket region is pivotal for the binding of NSPD-12m to gp41. These findings suggest that NSPD-12m can serve as a lead compound to develop novel virus entry inhibitors.
Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent Hiv-1 Inhibitors Based on Single Human Cd4 and Antibody Domains

Weizao Chen,Yang Feng,Ponraj Prabakaran,Tianlei Ying,Yanping Wang,Jianping Sun,Camila D. S. Macedo,Zhongyu Zhu,Yuxian He,Victoria R. Polonis,Dimiter S. Dimitrov

DOI: https://doi.org/10.1128/jvi.02566-13

IF: 6.549

2014-01-01

Journal of Virology

Abstract:ABSTRACT Soluble forms of the human immunodeficiency virus type 1 (HIV-1) primary receptor CD4 (soluble CD4 [sCD4]) have been extensively characterized for a quarter of a century as promising HIV-1 inhibitors, but they have not been clinically successful. By combining a protein cavity-filling strategy and the power of library technology, we identified an engineered cavity-altered single-domain sCD4 (mD1.22) with a unique combination of excellent properties, including broad and potent neutralizing activity, high specificity, stability, solubility, and affinity for the HIV-1 envelope glycoprotein gp120, and small molecular size. To further improve its neutralizing potency and breadth, we generated bispecific multivalent fusion proteins of mD1.22 with another potent HIV-1 inhibitor, an antibody domain (m36.4) that targets the coreceptor-binding site on gp120. The fusion proteins neutralized all HIV-1 isolates tested, with potencies about 10-, 50-, and 200-fold higher than those of the broadly neutralizing antibody VRC01, the U.S. FDA-approved peptide inhibitor T20, and the clinically tested sCD4-Fc fusion protein CD4-Ig, respectively. In addition, they exhibited higher stability and specificity and a lower aggregation propensity than CD4-Ig. Therefore, mD1.22 and related fusion proteins could be useful for HIV-1 prevention and therapy, including eradication of the virus.

A principled approach to setting optimal diagnostic thresholds: where ROC and indifference curves meet.

Does stage of change predict improved intimate partner violence outcomes following an emergency department intervention?

Acute systemic melioidosis: an autopsy study of six cases.

Inhibition of MAPK stimulates the Ca2+-dependent big-conductance K channels in cortical collecting duct

Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors

A minimally cytotoxic CD4 mimic as an HIV entry inhibitor

Healing of the bone incision following Le Fort I osteotomy.

In Silico Identification of Novel Aromatic Compounds As Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4

Hybrids of small CD4 mimics and gp41-related peptides as dual-target HIV entry inhibitors

In Silico Identification of High-Affinity Ligands of the Hiv-1 Gp120 Protein, Potential Peptidomimetics of Neutralizing Antibody N6

N-Phenyl-N'-(2,2,6,6-Tetramethyl-Piperidin-4-Yl)-Oxalamides As A New Class Of Hiv-1 Entry Inhibitors That Prevent Gp120 Binding To Cd4

Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4

Effect of modification of N-acetylneuraminic acid on the binding of glycoproteins to influenza virus and on susceptibility to cleavage by neuraminidase.

A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region

Structural Mimicry of CD4 by a Cross-reactive HIV-1 Neutralizing Antibody with CDR-H2 and H3 Containing Unique Motifs

Small-Molecule HIV Entry Inhibitors Targeting Gp120 and Gp41

Application of deep learning and molecular modeling to identify small drug-like compounds as potential HIV-1 entry inhibitors

Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule–Peptide Conjugates As New HIV-1 Fusion Inhibitors

IDENTIFICATION OF FUNCTIONAL MIMETICS OF ANTI-HIV ANTIBODY N6 BY METHODS OF VIRTUAL SCREENING AND MOLECULAR MODELING

N-Substituted Pyrrole Derivative 12m Inhibits HIV-1 Entry by Targeting Gp41 of HIV-1 Envelope Glycoprotein

Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent Hiv-1 Inhibitors Based on Single Human Cd4 and Antibody Domains